1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  04:58 2022-07-05 am EDT
10769.00 GBX   -0.36%
03:43aAstraZeneca Moves to Boost Blood Cancer Pipeline Via $1.3 Billion TeneoTwo Acquisition
MT
03:30aAstraZeneca to Buy TeneoTwo in Up to $1.27 Billion Deal
MT
02:24aAstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
11054(c) 10794(c) 10722(c) 10822(c) 10796 Last
1 504 553 2 377 056 1 981 487 665 137 128 442 Volume
+2.48% -2.35% -0.67% +0.93% -0.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 43 717 M - -
Net income 2022 4 956 M - -
Net Debt 2022 24 403 M - -
P/E ratio 2022 40,4x
Yield 2022 2,25%
Sales 2023 46 687 M - -
Net income 2023 8 020 M - -
Net Debt 2023 20 158 M - -
P/E ratio 2023 25,4x
Yield 2023 2,36%
Capitalization 203 B 203 B -
EV / Sales 2022 5,20x
EV / Sales 2023 4,78x
Nbr of Employees 83 100
Free-Float 96,4%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Ratings of AstraZeneca PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ASTRAZENECA PLC
03:43aAstraZeneca Moves to Boost Blood Cancer Pipeline Via $1.3 Billion TeneoTwo Acquisition
MT
03:30aAstraZeneca to Buy TeneoTwo in Up to $1.27 Billion Deal
MT
02:24aAstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion
RE
02:23aAstraZeneca To Buy TeneoTwo in Up tp $1.27 Billion Deal
MT
12:31aAstraZeneca to Buy TeneoTwo for Up to $1.27 Billion
DJ
07/01SECTOR UPDATE : Health Care Stocks Rebound Late
MT
07/01SECTOR UPDATE : Health Care Stocks Struggling for Direction
MT
07/01AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
MT
07/01AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination..
BU
07/01AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® Combinations in Patients..
CI
07/01AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica
MT
07/01New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten ..
AQ
07/01Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN..
AQ
07/01Pharmaceutical companies still have the upper hand
07/01Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility
DJ
More news
News in other languages on ASTRAZENECA PLC
03:57aASTRAZENECA : acquisition de TeneoTwo
03:43aAstraZeneca cherche à renforcer son portefeuille de produits pour le traitement du canc..
03:30aAstraZeneca va racheter TeneoTwo pour un montant maximum de 1,27 milliard de dollars.
03:07aLe retour du duty free ?
02:36aEN DIRECT DES MARCHES : Renault, Valeo, Elis, Valora, Sainsbury, Uniper, SAS, AstraZeneca,..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 130,92 $
Average target price 142,37 $
Spread / Average Target 8,74%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC24.71%202 861
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782